Stokes Frank's Form 4 filing
Castle Biosciences IncCSTL · filed Mar 5, 2026
- Accession no.
- 0001628280-26-015334
- Filed
- Mar 5, 2026
- Trade date
- Mar 3-4, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 4 derivative transactions. Open-market sales total $192.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Stokes FrankCIK 0001782815 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | Common Stock | SSaleDisposed | −5,300 | $27.32F2 | −$144,796 | 54,183 | Direct | |
| Mar 3, 2026 | Common Stock | SSaleDisposed | −1,700 | $27.81F4 | −$47,277 | 52,483 | Direct | |
| Mar 3, 2026 | Common Stock | FTax withholdingDisposed | −3,611 | $27.57 | −$99,555.27 | 48,872 | Direct | |
| Mar 4, 2026 | Common Stock | MOption exerciseAcquired | +24,146 | –F6 | – | 73,018 | Direct | |
| Mar 4, 2026 | Common Stock | FTax withholdingDisposed | −10,732 | $28.17 | −$302,320.44 | 62,286 | Direct | |
| Mar 4, 2026 | Common Stock | MOption exerciseAcquired | +3,800 | $3.38 | +$12,844 | 66,086 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | Common Stock | AGrant or awardAcquired | +48,367 | $0.00 | $0 | 48,367 | Direct | |
| Mar 4, 2026 | Common Stock | MOption exerciseDisposed | −12,186 | $0.00 | $0 | 24,372 | Direct | |
| Mar 4, 2026 | Common Stock | MOption exerciseDisposed | −11,960 | $0.00 | $0 | 35,878 | Direct | |
| Mar 4, 2026 | Common Stock | MOption exerciseDisposed | −3,800 | $0.00 | $0 | 14,912 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $26.70 to $27.67, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $27.72 to $27.97, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F6
Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
Referenced by the price of 1 transaction in Table I.